Gamma-Secretase, ErbB4 nuclear localization and neuregulin expression correlates with prostate cancer patient clinical outcome No significant financial relationships to disclose. This is an ASCO ...
Background: Primary uterine papillary serous carcinoma (UPSC), ovarian papillary serous carcinoma (OPSC), and peritoneal papillary serous carcinoma (PPSC) share histologic features and are ...
The highest rates of HER2 positivity were observed in bladder cancer, uterine serous carcinoma, and esophagogastric junction cancer. New research suggests the incidence of HER2 positivity is low ...
When you have breast cancer, one of the most important things to know is whether the cancer is at an early stage or if it has spread. Stage, type, size, and location of your tumor all can play a role ...
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, ...
Please provide your email address to receive an email when new articles are posted on . Tiersten: Historically HER2-positive breast cancers were considered to have a poor prognosis compared with other ...
Imlunestrant is approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, showing improved progression-free survival with abemaciclib. The oral administration of ...
The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback